These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25058908)

  • 1. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Igreja B; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2014 Oct; 740():285-94. PubMed ID: 25058908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
    Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
    Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.
    Loureiro AI; Rocha JF; Fernandes-Lopes C; Nunes T; Wright LC; Almeida L; Soares-da-Silva P
    Br J Clin Pharmacol; 2014 Jun; 77(6):1017-26. PubMed ID: 24168152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.
    Pires NM; Igreja B; Moura E; Wright LC; Serrão MP; Soares-da-Silva P
    Hypertens Res; 2015 Sep; 38(9):605-12. PubMed ID: 25854989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.
    Rocha JF; Vaz-Da-Silva M; Nunes T; Igreja B; Loureiro AI; Bonifácio MJ; Wright LC; Falcão A; Almeida L; Soares-Da-Silva P
    J Clin Pharmacol; 2012 Feb; 52(2):156-70. PubMed ID: 21343348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.
    Nunes T; Rocha JF; Vaz-da-Silva M; Igreja B; Wright LC; Falcão A; Almeida L; Soares-da-Silva P
    Drugs R D; 2010; 10(4):225-42. PubMed ID: 21171669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.
    Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
    Drug Metab Dispos; 2013 Dec; 41(12):2081-6. PubMed ID: 24013186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453).
    Vaz-da-Silva M; Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
    Drugs R D; 2011; 11(2):127-36. PubMed ID: 21548660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.
    Igreja B; Wright LC; Soares-da-Silva P
    J Am Soc Hypertens; 2016 Mar; 10(3):207-16. PubMed ID: 26803288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
    Pires NM; Loureiro AI; Igreja B; Lacroix P; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 750():98-107. PubMed ID: 25641747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase.
    Beliaev A; Learmonth DA; Soares-da-Silva P
    J Med Chem; 2006 Feb; 49(3):1191-7. PubMed ID: 16451083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey.
    Loureiro AI; Soares-da-Silva P
    Xenobiotica; 2015; 45(10):903-11. PubMed ID: 25869244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice.
    Armando I; Asico LD; Wang X; Jones JE; Serrão MP; Cuevas S; Grandy DK; Soares-da-Silva P; Jose PA
    Hypertens Res; 2018 Jul; 41(7):489-498. PubMed ID: 29654295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.
    Hegde SS; Friday KF
    Curr Pharm Des; 1998 Dec; 4(6):469-79. PubMed ID: 10197057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
    Stanley WC; Li B; Bonhaus DW; Johnson LG; Lee K; Porter S; Walker K; Martinez G; Eglen RM; Whiting RL; Hegde SS
    Br J Pharmacol; 1997 Aug; 121(8):1803-9. PubMed ID: 9283721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine β hydroxylase as a potential drug target to combat hypertension.
    Dey SK; Saini M; Prabhakar P; Kundu S
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1043-1057. PubMed ID: 32658551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.